PCRX – pacira biosciences, inc. (US:NASDAQ)
Stock Stats
News
Levi & Korsinsky Announces an Investigation on Behalf of Pacira BioSciences, Inc. (PCRX) Shareholders Who May Have Been Affected by Fraud
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee [Yahoo! Finance]
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $25.00 to $17.00. They now have an "equal weight" rating on the stock.
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Form 10-Q Pacira BioSciences, Inc. For: Sep 30
Form 8-K Pacira BioSciences, Inc. For: Oct 31
Form 4 Pacira BioSciences, Inc. For: Nov 01 Filed by: Cross Shawn
Form 3 Pacira BioSciences, Inc. For: Oct 21 Filed by: Cross Shawn
Form 8-K Pacira BioSciences, Inc. For: Oct 16
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.